The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

The healthcare company also struck a deal with Novo Nordisk to sell Wegovy at a reduced price for cash-paying customers ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy ... Transgender issues are a strength ...

Zepbound's prescription growth has surged ahead of Novo Nordisk's rival GLP-1 weight-loss drug Wegovy in recent months after struggles with supply issues ... said the CVS coverage decision will ...

But employers and unions will ultimately determine how much of those savings on Wegovy get shared with members, CVS said ... the weight loss drug market and concerns that Zepbound's sales ...